Q4 Earnings Forecast for Amgen Issued By Leerink Partnrs

Amgen Inc. (NASDAQ:AMGNFree Report) – Stock analysts at Leerink Partnrs cut their Q4 2024 EPS estimates for shares of Amgen in a research note issued to investors on Wednesday, November 27th. Leerink Partnrs analyst D. Risinger now forecasts that the medical research company will post earnings per share of $4.97 for the quarter, down from their prior forecast of $5.01. The consensus estimate for Amgen’s current full-year earnings is $19.52 per share. Leerink Partnrs also issued estimates for Amgen’s FY2025 earnings at $20.33 EPS and FY2028 earnings at $19.41 EPS.

A number of other equities analysts also recently issued reports on AMGN. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Thursday. Truist Financial downgraded shares of Amgen from a “buy” rating to a “hold” rating and raised their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th. UBS Group dropped their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Finally, TD Cowen raised their price objective on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $323.05.

View Our Latest Report on AMGN

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $282.87 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a market cap of $152.05 billion, a PE ratio of 36.22, a PEG ratio of 2.50 and a beta of 0.60. The firm’s 50-day moving average price is $311.37 and its 200-day moving average price is $317.14. Amgen has a 52-week low of $257.80 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGNGet Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the firm posted $4.96 EPS.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.18%. The ex-dividend date is Monday, November 18th. Amgen’s payout ratio is currently 115.24%.

Institutional Investors Weigh In On Amgen

Large investors have recently bought and sold shares of the business. Capital Performance Advisors LLP bought a new stake in Amgen in the third quarter worth $25,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the second quarter worth $30,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the third quarter worth $29,000. nVerses Capital LLC bought a new stake in Amgen in the second quarter worth $31,000. Finally, Bbjs Financial Advisors LLC bought a new stake in Amgen in the second quarter worth $33,000. Institutional investors own 76.50% of the company’s stock.

About Amgen

(Get Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Stories

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.